Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of TICOVAC in Children
NCT00161746Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 1998
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Tick-borne encephalitis vaccine in tick-borne encephalitis (TBE) (2 arms), sponsored by Pfizer. Primary endpoint: Seroconversion Rate. Started Apr 1998; status: completed.
02
Drugs
Tick-borne encephalitis vaccine
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on NCT00161746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00161746.